December 11, 2012 Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients
[at noodls] – December 11, 2012 Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients Promising clinical response activity … more
View todays social media effects on AEZS
View the latest stocks trending across Twitter. Click to view dashboard